6 Things I Wish I Knew Before Starting Oral GLP-1s for Obesity

1. The Pill Won’t Do All the Work for You
When Kris R. started taking semaglutide (Wegovy), an oral GLP-1, in March 2026, she thought the weight would simply melt off. “I thought it was a miracle pill, and that it did the work,” Kris says. “But it kind of just helps you do the work.”
For Nusha Nouhi, PhD, a clinical psychologist based in San Diego, both the oral and injectable GLP-1s have helped quiet the “food noise,” but neither treatment has changed her relationship with food.
Nouhi began using GLP-1 medications in 2021, starting with the daily injectable liraglutide (Saxenda), then moving to the weekly injectable Wegovy and weekly injectable tirzepatide (Zepbound). She switched to daily oral semaglutide in March 2026. She has lost about 50 lb over her five-year GLP-1 journey, which included taking some time off the treatment.
C. Herrera, a Florida-based medical professional, took weekly injectable semaglutide (Ozempic) for about two years before switching to daily oral semaglutide. Neither treatment, she’s found, has replaced the need to make healthy lifestyle choices. She still has to plan meals, make thoughtful food choices, and stay active, even when fatigue and other health concerns make that more challenging.
2. You May Not Want to Take a Pill in the Morning
For some people, that’s no big deal. For others, it’s a logistical hurdle.
Kris, for instance, isn’t bothered by the 30-minute wait. “You could wake up, take it first thing, take your shower, get dressed, and those 30 minutes are up,” she says. But she recognizes that the routine might feel different for someone racing to work or trying to take several morning medications in the correct order.
That’s the case for Herrera, who sometimes struggles to take the pill — and accommodate the 30-minute wait time — in the morning rush to eat breakfast and get out the door.
3. You Might Have Different Results on an Oral GLP-1
Both Nouhi and Herrera say the oral GLP-1s are more convenient, but they also believe they lost more weight on the injectables.
Nouhi, for instance, travels frequently, and carrying a bottle of tablets is easier than traveling with injection pens. She now takes the maximum 25 milligrams (mg) dose of the Wegovy pill. Despite the convenience, she still thinks her body responded best to Zepbound, an injectable.
Herrera also believes the Wegovy pill has produced less weight loss and taken longer to work than Ozempic, an injection. Even so, she continues taking the tablet because it has been easier for her to tolerate.
These experiences don’t mean injections are always more effective for everyone — rather, that switching from an injection to a tablet, even when the medications contain the same active ingredient, might produce different results.
4. The Side Effects Can Still Be Disruptive
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal discomfort
For Herrera, the side effects from an oral GLP-1 aren’t as intense as those from an injectable GLP-1, but they are still bothersome. While taking Ozempic, Herrera experienced significant nausea and vomiting that eventually eased, followed by constipation and diarrhea, which didn’t. She stopped taking the injections and eventually switched to Wegovy.
While the digestive symptoms have been milder on the pill, Herrera says they still occur every day.
Kris, however, has noticed far fewer side effects. She occasionally feels queasy, but can’t tell whether her symptoms are caused by Wegovy or another medication she takes that can also cause nausea. Overall, she says, she hasn’t experienced a change in how she feels since starting an oral GLP-1.
5. There May Still Be ‘Food Noise’
Although it isn’t a formal medical diagnosis, “food noise” became a familiar term after people began taking GLP-1s. It describes persistent, unwanted thoughts about food, such as thinking about your next snack or feeling distracted by what you might eat later.
Starting a GLP-1 quieted those thoughts noticeably for Nouhi. “I had no idea how loud food noise was until it went quiet, and then I had all this time and mental space back,” she says.
Kris also thought less about snacks and felt less pulled toward food around her after she started taking the Wegovy pill. She recalls watching a friend order a burger and fries — something that normally would have caught her attention — and not feeling tempted to grab a fry.
After about four months, though, that feeling began to fade. She felt the urge to snack at night again and found herself thinking about food more often.
Kris’s experience with food noise isn’t the case for everyone, but if persistent thoughts about food return while you’re taking an oral GLP-1, it’s worth mentioning it to your healthcare provider. They can help you evaluate whether your treatment plan needs adjusting.
6. Food Still Tastes Good
Before starting the Wegovy pill, Kris wondered whether she’d ever enjoy eating again.
“I thought maybe food wouldn’t taste good, and that would somehow be the deterrent to eating,” Kris says. “I was pleasantly surprised to see that’s not an issue at all.”
Resources We Trust
- Cleveland Clinic: How to Keep Weight Off With GLP-1s
- Mayo Clinic: Pros and Cons of GLP-1 Agonists for Weight Loss
- Yale Medicine: GLP-1 Weight-Loss Pills: What You Need to Know
- Obesity Action Coalition: GLP-1 Medications and Side Effects: What Patients Should Know
- Mount Sinai Today: What Are the Benefits of the New GLP-1 Weight Loss Pills?
- GLP-1 Agonists. Cleveland Clinic. July 3, 2023.
- FDA Approves Novo Nordisk's Wegovy® Pill, The First and Only Oral GLP-1 For Weight Loss in Adults. PR Newswire. December 22, 2025.
- WEGOVY- Semaglutide Injection, Solution WEGOVY- Semaglutide Tablet. DailyMed. June 18, 2026.
- FOUNDAYO- Orforglipron Tablet, Film Coated. DailyMed. July 29, 2026.
- Aldawsari M et al. The Efficacy of GLP-1 Analogues on Appetite Parameters, Gastric Emptying, Food Preference and Taste Among Adults with Obesity: Systematic Review of Randomized Controlled Trials. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. January 14, 2023.
- Du et al. Altered Eating Experience During GLP-1 Receptor Agonist Therapy: A Sensory-Liking-Wanting Framework for Food Preference and Nutritional Behaviour. Frontiers in Nutrition. July 16, 2026.

Pooja Singhal, MD
Medical Reviewer
Pooja Singhal, MD, FACG, DABOM, is a board-certified gastroenterologist, hepatologist, and obesity medicine specialist. She completed her medical school training at the University ...

Maggie Aime, MSN, RN
Author
Maggie Aime is a registered nurse with over 25 years of healthcare experience, who brings medical topics to life through informative and inspiring content. Her extensive nursing ba...